Irritability in bipolar disorder and unipolar disorder measured daily using smartphone-based data: An exploratory post hoc study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 952 KB, PDF-dokument

Objective: To investigate (i) the proportions of time with irritability and (ii) the association between irritability and affective symptoms and functioning, stress, and quality of life in patients with bipolar disorder (BD) and unipolar depressive disorder (UD). Methods: A total of 316 patients with BD and 58 patients with UD provided self-reported once-a-day data on irritability and other affective symptoms using smartphones for a total of 64,129 days with observations. Questionnaires on perceived stress and quality of life and clinical evaluations of functioning were collected multiple times during the study. Results: During a depressive state, patients with UD spent a significantly higher proportion of time with presence of irritability (83.10%) as compared with patients with BD (70.27%) (p = 0.045). Irritability was associated with lower mood, activity level and sleep duration and with increased stress and anxiety level, in both patient groups (p-values<0.008). Increased irritability was associated with impaired functioning and increased perceived stress (p-values<0.024). In addition, in patients with UD, increased irritability was associated with decreased quality of life (p = 0.002). The results were not altered when adjusting for psychopharmacological treatments. Conclusions: Irritability is an important part of the symptomatology in affective disorders. Clinicians could have focus on symptoms of irritability in both patients with BD and UD during their course of illness. Future studies investigating treatment effects on irritability would be interesting.

OriginalsprogEngelsk
TidsskriftActa Psychiatrica Scandinavica
Vol/bind147
Udgave nummer6
Sider (fra-til)593-602
Antal sider10
ISSN0001-690X
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
The RADMIS trial was funding by Innovation Fund Denmark (5164‐00001B9). The BIO study was funded by grants from the Mental Health Services, Capital Region of Denmark, The Danish Council for Independent Research, Medical Sciences (DFF‐4183‐00570), Weimans Fund, Markedmodningsfonden (the Market Development Fund, (2015‐310), Gangstedfonden (A29594), Helsefonden (16‐B‐0063), Innovation Fund Denmark (the Innovation Fund, Denmark, 5164‐00001B), Copenhagen Center for Health Technology (CACHET), EU H2020 ITN (EU project 722561), Augustinusfonden (16‐0083), and Lundbeck Foundation (R215‐2015‐4121). The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Publisher Copyright:
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk


Ingen data tilgængelig

ID: 352037545